Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for ACADIA Pharmaceuticals Inc. (ACAD : NSDQ)

• Company Description    Acadia Pharmaceuticals Inc. is a biopharmaceutical company focused on developing innovative medicines to address the unmet medical needs in central nervous system (CNS) disorders. The company's sole marketed drug Nuplazid (pimavanserin) is the first and the only FDA-approved treatment for hallucinations and delusions associated with Parkinson's disease psychosis. The company suffered a setback when the FDA issued a complete response letter to the supplemental new drug application for Nuplazid for treating dementia-related psychosis. Acadia resubmitted the supplemental new drug application to the FDA for pimavanserin for the treatment of hallucinations and delusions associated with Alzheimer's disease psychosis. Notably, several additional studies on Nuplazid n targeting different CNS indications, such as?dementia-related psychosis, schizophrenia inadequate response, schizophrenia negative symptoms and as an adjunctive treatment of major depressive disorder (MDD) are currently underway. Number of Employees: 798

• Price / Volume Information    Yesterday's Closing Price: $24.56 Daily Weekly Monthly 20 Day Moving Average: 1,662,933 shares Shares Outstanding: 170.49 (millions) Market Capitalization: $4,187.35 (millions) Beta: 0.66 52 Week High: $28.35 52 Week Low: $13.40 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week -2.27% -1.41% 12 Week -10.50% -10.61% Year To Date -8.05% -8.50%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 12830 El Camino Real Suite 400 - SAN DIEGO,CA 92130 USA ph: 858-558-2871 fax: 858-558-2872 ir@acadia-pharm.com http://www.acadia.com

• General Corporate Information    Officers Catherine Owen Adams - Chief Executive Officer Stephen R. Biggar - Chairman of the Board Mark C. Schneyer - Executive Vice President and Chief Financial Offic James K. Kihara - Senior Vice President; Finance Julian C. Baker - Director Peer Information ACADIA Pharmaceuticals Inc. (CORR.) ACADIA Pharmaceuticals Inc. (RSPI) ACADIA Pharmaceuticals Inc. (CGXP) ACADIA Pharmaceuticals Inc. (BGEN) ACADIA Pharmaceuticals Inc. (GTBP) ACADIA Pharmaceuticals Inc. (RGRX) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-BIOMED/GENE Sector: Medical CUSIP: 004225108 SIC: 2834 Fiscal Year Fiscal Year End: December Last Reported Quarter: 12/01/25 Next Expected EPS Date: 05/06/26 Share - Related Items Shares Outstanding: 170.49 Most Recent Split Date: (:1) Beta: 0.66 Market Capitalization: $4,187.35 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $0.09 Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $0.48 Payout Ratio: 0.00 Number of Estimates in the Fiscal Year Consensus: 12.00 Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: 2.14% Last Dividend Paid: NA - $0.00 Next EPS Report Date: 05/06/26

• Fundamental Ratios P/E Current FY Estimate: 50.99 Trailing 12 Months: 35.59 PEG Ratio: 23.83 Price Ratios Price/Book: 3.39 Price/Cash Flow: 27.68 Price / Sales: 3.91 EPS Growth vs. Year Ago Period: -5.88% vs. Previous Quarter: -38.46% Sales Growth vs. Year Ago Period: 9.39% vs. Previous Quarter: 1.92% ROE 12/31/25 - 12.49 09/30/25 - 14.61 06/30/25 - 14.69 ROA 12/31/25 - 8.88 09/30/25 - 9.70 06/30/25 - 9.41 Current Ratio 12/31/25 - 3.83 09/30/25 - 3.02 06/30/25 - 2.91 Quick Ratio 12/31/25 - 3.71 09/30/25 - 2.94 06/30/25 - 2.83 Operating Margin 12/31/25 - 10.88 09/30/25 - 11.29 06/30/25 - 10.44 Net Margin 12/31/25 - 36.49 09/30/25 - 24.94 06/30/25 - 21.80 Pre-Tax Margin 12/31/25 - 12.96 09/30/25 - 26.14 06/30/25 - 26.29 Book Value 12/31/25 - 7.25 09/30/25 - 5.42 06/30/25 - 4.87 Inventory Turnover 12/31/25 - 3.15 09/30/25 - 3.38 06/30/25 - 2.48 Debt-to-Equity 12/31/25 - 0.00 09/30/25 - 0.00 06/30/25 - 0.00 Debt-to-Capital 12/31/25 - 0.00 09/30/25 - 0.00 06/30/25 - 0.00

Powered by Zacks Investment Research ©